Zydus launches generic diabetes drug in India

11 December 2019

Zydus Cadila, part of India’s Cadila Healthcare (BOM: 532321), has launched a generic diabetes drug in the Asian country.

The company’s products, Vinglyn (vildagliptin) and Vinglyn M (vildagliptin/metformin) belong to a class of oral anti-diabetic agents, known as DPP4 inhibitors, that can help achieve glycemic control without deterioration in beta cell function.

They will be priced at around one sixth of the price at which the patented vildagliptin was initially launched in India. The reference drug was branded under the names Galvus and Zomelis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK